Yinghong Wang, M.D., Ph.D., M.S.

Peer-Reviewed Articles

1. Fayle SE, Palaskas NL, Siddiqui BA, McQuade JL, Lin JS, Subudhi SK, Patel AB, Jenq RR, Shah AY, Spelman AR, Sun M, Marble BH, Wang Y. Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events. J Natl Compr Canc Netw:1-8. e-Pub 2024. PMID: 38190801.
2. Harvey C, Nahar KJ, McKeown J, Lo SN, Farag S, Yousaf N, Young K, Tas L, Meerveld-Eggink A, Blank C, Thomas A, McQuade J, Schilling B, Johnson DB, Huertas RM, Arance A, Lee J, Zimmer L, Long GV, Carlino MS, Wang Y, Menzies AM. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series. J Immunother Cancer 12(1), 2024. e-Pub 2024. PMID: 38296594.
3. Shatila M, Eshaghi F, Thomas AR, Kuang AG, Shah JS, Zhao B, Naz S, Sun M, Fayle S, Jin J, Abudayyeh A, Sheshadri A, Palaskas NL, Franco-Vega MC, Gaeta MS, Thomas AS, Zhang HC, Wang Y. Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center. Cancers (Basel) 16(2), 2024. e-Pub 2024. PMID: 38254858.
4. Joerg V, Scheiner B, D Alessio A, Fulgenzi CAM, Schönlein M, Kocheise L, Lohse AW, Huber S, Wege H, Kaseb A, Wang Y, Mathew A, Kuang A, Muzaffar M, Abugabal YI, Chamseddine S, Phen S, Cheon J, Lee PC, Balcar L, Krall A, Ang C, Wu L, Saeed A, Huang YH, Bengsch B, Rimassa L, Weinmann A, Stauber R, Korolewicz J, Pinter M, Singal AG, Chon HJ, Pinato DJ, Schulze K, von Felden J. Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study. Hepatol Commun 7(11), 2023. e-Pub 2023. PMID: 37889520.
5. Khalil Choucair, Caroline Nebhan, Alessio Cortellini, Stijn Hentzen, Yinghong Wang, Cynthia Liu, April K. Salama, Andrew Elliott, Matthew James Oberley, Phillip Walker, Raffaele Giusti, Marco Filetti, Paolo Antonio Ascierto, Vito Vanella, Domenico Galetta, Annamaria Catino, Pamela Pizzutilo, ,Carlo Genova, Melissa Bersanelli, Sebastiano, Buti, Azhar Saeed, Hirva Mamdani, Dipesh Uprety, Wafik S. El-Deiry, Himisha Beltran, Chadi Nabhan, Douglas B. Johnson, Claudia, Angela Maria Fulgenzi,David J. Pinato, Maluki Radford, Stephen V. Liu, Chul Kim, Abdul Rafeh Naqash, Anwaar Saeed. Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival. Cancers, 2023.
6. Sperling Gabriel,Wang Y. Pouchitis After Immune Checkpoint Inhibitors. Annals of Internal Medicine Clinical Cases 2023 2(8), 2023. e-Pub 2023.
7. Antonio Pizuorno Machado, Malek Shatila, Enrico N. De Toni, Helga-Paula Török, Jessica Philpott, Dan Zhao, Yan Zhou, Krishnavathana Varatharajalu, Mehnaz A. Shafi, Hao Chi Zhang, Anusha S. Thomas, Yinghong Wang. Colon Adenoma After Diagnosis of Immune Checkpoint Inhibitor–mediated Colitis. Journal of Cancer 14(14):2686 - 2693, 2023. e-Pub 2023.
8. Abu-Sbeih H, Tang T, Ali FS, Ma W, Shatila M, Luo W, Tan D, Tang C, Richards DM, Ge PS, Thomas AS, Wang Y. Clinical Features and Management of Acute and Chronic Radiation-Induced Colitis and Proctopathy. Cancers(15):3160, 2023.
9. Halsey TM, Thomas AS, Hayase T, Ma W, Abu-Sbeih H, Sun B, Parra ER, Jiang ZD, DuPont HL, Sanchez C, El-Himri R, Brown A, Flores I, McDaniel L, Ortega Turrubiates M, Hensel M, Pham D, Watowich SS, Hayase E, Chang CC, Jenq RR, Wang Y. Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis. Sci Transl Med 15(700):eabq4006, 2023. e-Pub 2023. PMID: 37315113.
10. Badran YR, Zou F, Durbin SM, Dutra BE, Abu-Sbeih H, Thomas AS, Altan M, Thompson JA, Qiao W, Leet DE, Lai PY, Horick NK, Postow MA, Faleck DM, Wang Y, Dougan M. Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis. J Immunother Cancer 11(6), 2023. PMID: 37349130.
11. Kuang AG, Sperling G, Liang TZ, Lu Y, Tan D, Bollin K, Johnson DB, Manzano JM, Shatila M, Thomas AS, Thompson JA, Zhang HC, Wang Y. Sclerosing mesenteritis following immune checkpoint inhibitor therapy. J Cancer Res Clin Oncol. e-Pub 2023. PMID: 37195298.
12. Shatila M, Ma W, Cui Y, Naz S, S Thomas A, N De Toni E, Török HP, Khaled NB, Altan M, Schneider B, Wang Y. Effects of immunosuppressive treatment on patient outcomes after immune checkpoint inhibitor-related gastrointestinal toxicity. J Cancer Res Clin Oncol. e-Pub 2023. PMID: 37029815.
13. Wang Y, Jenq RR, Wargo JA, Watowich SS. Microbiome influencers of checkpoint blockade-associated toxicity. J Exp Med 220(3), 2023. e-Pub 2023. PMID: 36622383.
14. Dutra B, Garcia-Rodriguez V, Garcia R, Szafron D, Abraham F, Khurana S, Lockhart J, Amin R, Wang Y, Thomas A. Characteristics and Outcomes of Cancer Patients With Venous Thromboembolic Events After Treatment With Immune Checkpoint Inhibitors. Am J Clin Oncol 46(3):94-100, 2023. e-Pub 2023. PMID: 36735530.
15. Hanauer S, Wang Y, Shatila M. Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther 57(1):150-151, 2023. e-Pub 2022. PMID: 36468245.
16. Kuang AG, Mohajir W, Panneerselvam K, McQuade JL, Oliva ICG, Khan MA, Zhang HC, Thomas AS, Wang Y. Diarrhea and colitis related to immune checkpoint inhibitor and BRAF/MEK inhibitor therapy. Ann Gastroenterol 36(1):45-53, 2023. e-Pub 2022. PMID: 36593813.
17. Liu C, Shatila M, Mathew A, Machado AP, Thomas A, Zhang HC, Thomas AS, Faleck D, Funchain P, Philpott J, Grivas P, Obeid M, Carbonnel F, Wang Y. Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer. J Cancer 14(10):1913-1919, 2023. e-Pub 2023. PMID: 37476185.
18. Machado AP, Ratliff H, Abdelwahab A, Vohra MH, Kuang A, Shatila M, Khan MA, Shafi MA, Thomas AS, Philpott J, Alhalabi O, Wang Y. The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: a Systematic Review. J Cancer 14(16):2956-2963, 2023. e-Pub 2023. PMID: 37859810.
19. Kovalenko I, Lynn Ng W, Geng Y, Wang Y, Msaouel P, Bhatia S, Grivas P, Benkhadra R, Alhalabi O. Adverse events of immune checkpoint therapy alone versus when combined with vascular endothelial growth factor inhibitors: a pooled meta-analysis of 1735 patients. Front Oncol 13:1238517, 2023. e-Pub 2024. PMID: 38239644.
20. Altan M, Li QZ, Wang Q, Vokes NI, Sheshadri A, Gao J, Zhu C, Tran HT, Gandhi S, Antonoff MB, Swisher S, Wang J, Byers LA, Abdel-Wahab N, Franco-Vega MC, Wang Y, Lee JJ, Zhang J, Heymach JV. Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events. Front Immunol 14:1322818, 2023. e-Pub 2023. PMID: 38152395.
21. Gabriel Sperling, Malek Shatila, Krishnavathan Varatharajalu, Yang Lu, Mehmet Altan, Yan Zhou, Dan Zhao, Enrico N. De Toni, Helga-Paula Török, Bryan J Schneider, Anam Khan, Anusha S Thomas, Hao Chi Zhang, Yinghong Wang. Pneumatosis intestinalis/coli in cancer patients who received immune checkpoint inhibitors. Journal of Cancer Research and Clinical Oncology, 2023.
22. Anusha Shirwaikar Thomas, Michael Abreo, Sayed Ahmed Sayed, Sai Prasada Rao Manikonda, Mostafa Eyada, Aaron Issac, Fiyinfoluwa Abraham, Jake Sheraj Jacob, Yinghong Wang, Sireesha Yedururi, Suresh T Chari. Immune checkpoint Inhibitor-induced pancreatic injury Clinical and Radiological Profile and Response to Steroids. Gastro Hep Advances, 2023.
23. Shilpa Grover, MD, MPH, Yinghong Wang, MD, PhD, Michael Dougan, MD, PhD.. Immune Checkpoint Inhibitor Colitis, 2023.
24. Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33(12):1217-1238, 2022. e-Pub 2022. PMID: 36270461.
25. Thomas AR, Liu C, Tong YT, Tan D, Altan M, Siddiqui BA, Shatila M, Khan A, Thomas AS, Wang Y. Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors. J Cancer Res Clin Oncol. e-Pub 2022. PMID: 36451045.
26. Talbot T, D'Alessio A, Pinter M, Balcar L, Scheiner B, Marron TU, Jun T, Dharmapuri S, Ang C, Saeed A, Hildebrand H, Muzaffar M, Fulgenzi CAM, Amara S, Naqash AR, Gampa A, Pillai A, Wang Y, Khan U, Lee PC, Huang YH, Bengsch B, Bettinger D, Mohamed YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Kudo M, Weinmann A, Galle PR, Muhammed A, Cortellini A, Vogel A, Pinato DJ. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an international observational study. Liver Int. e-Pub 2022. PMID: 36577703.
27. Schwabkey ZI, Wiesnoski DH, Chang CC, Tsai WB, Pham D, Ahmed SS, Hayase T, Ortega Turrubiates MR, El-Himri RK, Sanchez CA, Hayase E, Frenk Oquendo AC, Miyama T, Halsey TM, Heckel BE, Brown AN, Jin Y, Raybaud M, Prasad R, Flores I, McDaniel L, Chapa V, Lorenzi PL, Warmoes MO, Tan L, Swennes AG, Fowler S, Conner M, McHugh K, Graf T, Jensen VB, Peterson CB, Do KA, Zhang L, Shi Y, Wang Y, Galloway-Pena JR, Okhuysen PC, Daniel-MacDougall CR, Shono Y, Burgos da Silva M, Peled JU, van den Brink MRM, Ajami N, Wargo JA, Reddy P, Valdivia RH, Davey L, Rondon G, Srour SA, Mehta RS, Alousi AM, Shpall EJ, Champlin RE, Shelburne SA, Molldrem JJ, Jamal MA, Karmouch JL, Jenq RR. Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci Transl Med 14(671):eabo3445, 2022. e-Pub 2022. PMID: 36383683.
28. Thomas AR, Eyada M, Kono M, Varatharajalu K, Lu Y, Xu G, Panneerselvam K, Shatila M, Altan M, Wang J, Thompson JA, Zhang HC, Khan MA, Raju GS, Thomas AS, Wang Y. Characteristics, treatment, and outcome of diverticulitis after immune checkpoint inhibitor treatment in patients with malignancies. J Cancer Res Clin Oncol. e-Pub 2022. PMID: 36242603.
29. Thomas AS, Hanauer S, Wang Y. Immune Checkpoint inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. e-Pub 2022. PMID: 36270617.
30. Thomas AS, Abreo M, Sayed SA, Sireesha Yedururi YW, Chari ST. Autoimmune Pancreatitis Secondary to Immune Checkpoint Inhibitor Therapy (Type 3 AIP): Insights Into a New Disease From Serial Pancreatic Imaging. Gastroenterology. e-Pub 2022. PMID: 36220459.
31. Saji A, Chopra M, Jacob J, Altan M, Alhalabi O, Shah AY, Qiao W, Wang Y, Thomas A. Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune‑mediated diarrhea and colitis. Journal of Cancer Research and Clinical Oncology, 2022.
32. Panneerselvam K, Szafron D, Amin RN, Wei D, Tan D, Altan M, Okhuysen PC, Shatila M, Raju GS, Thomas AS, Wang Y. Cytomegalovirus infection among patients with cancer receiving immune checkpoint inhibitors. Ann Gastroenterol 35(5):522-531, 2022. e-Pub 2022. PMID: 36061160.
33. Yu K, Mathew A, Abraham F, Amin R, Kono M, Overman M, Zhao D, Khan A, Khan MA, Thomas AS, Wang Y. Immune checkpoint inhibitor-related gastrointestinal toxicity in patients with malignancy involving the luminal gastrointestinal tract and its impact on cancer outcomes. Ann Gastroenterol 35(5):514-521, 2022. e-Pub 2022. PMID: 36061157.
34. Mathew A, Shatila M, Lai Z, Tan D, Oliva ICG, Wang J, Alhalabi O, Zhang HC, Thomas A, Wang Y. Characteristics of appendicitis after immune checkpoint inhibitor therapy among cancer patients. J Cancer Res Clin Oncol. e-Pub 2022. PMID: 36163559.
35. Hollander B, Khurana S, Jacob JS, Altan M, Wang J, Zhao D, Varatharajalu K, Alasadi M, Thomas AS, Wang Y. Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis. J Cancer Res Clin Oncol. e-Pub 2022. PMID: 35972690.
36. Liu C, Amin R, Shatila M, Short N, Altan M, Shah A, Alhalabi O, Okhuysen P, Thomas AS, Wang Y. Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects. J Cancer Res Clin Oncol. e-Pub 2022. PMID: 36030431.
37. Abu-Sbeih H, Szafron D, Elkafrawy AA, Garcia-Rodriguez V, Ma W, Xu A, Khurana S, Numan L, Chen E, Goldstein R, Tsen A, Peng Y, Blum M, Kopetz ES, Ikoma N, Shatila M, Qiao W, Raju GS, Ross WA, Ge PS, Coronel E, Wang Y. Endoscopy for the diagnosis and treatment of gastrointestinal bleeding caused by malignancy. J Gastroenterol Hepatol. e-Pub 2022. PMID: 35730192.
38. Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, Kim ST, Nurieva R, Lazar AJ, Abu-Sbeih H, Fa'ak F, Mathew A, Wang Y, Falohun A, Trinh V, Zobniw C, Spillson C, Burks JK, Awiwi M, Elsayes K, Soto LS, Melendez BD, Davies MA, Wargo J, Curry J, Yee C, Lizee G, Singh S, Sharma P, Allison JP, Hwu P, Ekmekcioglu S, Diab A. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 40(5):509-523.e6, 2022. e-Pub 2022. PMID: 35537412.
39. Sharma R, Pillai A, Marron TU, Fessas P, Saeed A, Jun T, Dharmapuri S, Szafron D, Naqash AR, Gampa A, Wang Y, Khan U, Muzaffar M, Lee CJ, Lee PC, Bulumulle A, Paul S, Bettinger D, Hildebrand H, Yehia M, Pressiani T, Kaseb A, Huang YH, Ang C, Kudo M, Nishida N, Personeni N, Rimassa L, Pinato DJ. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun. e-Pub 2022. PMID: 35481940.
40. Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, Bhatia S, Budde LE, Chokshi S, Davies M, Elshoury A, Gesthalter Y, Hegde A, Jain M, Kaffenberger BH, Lechner MG, Li T, Marr A, McGettigan S, McPherson J, Medina T, Mohindra NA, Olszanski AJ, Oluwole O, Patel SP, Patil P, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Zaha VG, Lyons M, Dwyer M, Hang L. Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20(4):387-405, 2022. PMID: 35390769.
41. Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. J Clin Oncol 39(35):JCO2101992, 2021. e-Pub 2021. PMID: 34724386.
42. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 39(36):JCO2101440, 2021. e-Pub 2021. PMID: 34724392.
43. Muhammed A, Fulgenzi CAM, Dharmapuri S, Pinter M, Balcar L, Scheiner B, Marron TU, Jun T, Saeed A, Hildebrand H, Muzaffar M, Navaid M, Naqash AR, Gampa A, Ozbek U, Lin JY, Perone Y, Vincenzi B, Silletta M, Pillai A, Wang Y, Khan U, Huang YH, Bettinger D, Abugabal YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Di Tommaso L, Kudo M, Vogel A, Mauri FA, Cortellini A, Sharma R, D'Alessio A, Ang C, Pinato DJ. The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. Cancers (Basel) 14(1), 2021. e-Pub 2021. PMID: 35008350.
44. Nebhan CA, Cortellini A, Ma W, Ganta T, Song H, Ye F, Irlmeier R, Debnath N, Saeed A, Radford M, Alahmadi A, Diamond A, Hoimes C, Ramaiya N, Presley CJ, Owen DH, Abou Alaiwi S, Nassar A, Ricciuti B, Lamberti G, Bersanelli M, Casartelli C, Buti S, Marchetti P, Giusti R, Filetti M, Vanella V, Mallardo D, Macherla S, Sussman TA, Botticelli A, Galetta D, Catino A, Pizzutilo P, Genova C, Dal Bello MG, Kalofonou F, Daniels E, Ascierto PA, Pinato DJ, Choueiri TK, Johnson DB, Marron TU, Wang Y, Naqash AR. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study. JAMA Oncol. e-Pub 2021. PMID: 34734989.
45. Zou F, Faleck D, Thomas A, Harris J, Satish D, Wang X, Charabaty A, Ernstoff MS, Glitza Oliva IC, Hanauer S, McQuade J, Obeid M, Shah A, Richards DM, Sharon E, Wolchok J, Thompson J, Wang Y. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer 9(11), 2021. PMID: 34789551.
46. Fessas P, Naeem M, Pinter M, Marron TU, Szafron D, Balcar L, Saeed A, Jun T, Dharmapuri S, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Pressiani T, Personeni N, Nishida N, Kudo M, Kaseb A, Huang YH, Ang C, Pillai A, Rimassa L, Naqash AR, Sharon E, Cortellini A, Pinato DJ. Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma. Liver Cancer 10(6):583-592, 2021. e-Pub 2021. PMID: 34950181.
47. Jacob JS, Dutra BE, Garcia-Rodriguez V, Panneerselvam K, Abraham FO, Zou F, Ma W, Grivas P, Thompson JA, Altan M, Oliva ICG, Zhang HC, Thomas AS, Wang Y. Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer. J Natl Compr Canc Netw. e-Pub 2021. PMID: 34348238.
48. Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis C. Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open 4(8):e2122998, 2021. e-Pub 2021. PMID: 34459906.
49. Qian W, Ye Y, Zuo L, Song T, Xu Q, Wang Y, Qian J, Tian Y. Immune checkpoint inhibitors use and effects on prognosis of COVID-19 infection: a systematic review and meta-analysis. Immunotherapy. e-Pub 2021. PMID: 34431319.
50. Ma W, Gong Z, Abu-Sbeih H, Peng Y, Peng F, Zou F, Charabaty A, Okhuysen PC, McQuade JL, Altan M, Zhang HC, Thomas AS, Wang Y. Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections. Am J Clin Oncol. e-Pub 2021. PMID: 34107499.
51. Khurana S, Abu-Sbeih H, Ma W, Qiao W, Foo WC, Richards DM, Thomas AS, Khan A, Zhang HC, Wang Y. Clinical Characteristics and Outcomes of Eosinophilic Colitis in Patients With Cancer. Am J Clin Oncol. e-Pub 2021. PMID: 34091476.
52. Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor (ICI) Colitis and Hepatitis: Expert Review. Gastroenterology 160(4):1384-1393, 2021. e-Pub 2020. PMID: 33080231.
53. Ma C, MacDonald JK, Nguyen TM, Vande Casteele N, Linggi B, Lefevre P, Wang Y, Feagan BG, Jairath V. Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review. Dig Dis Sci. e-Pub 2021. PMID: 33770330.
54. Thomas AS, Ma W, Wang Y. Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors. N Engl J Med 384(6):581-583, 2021. PMID: 33567198.
55. Zou F, Wang X, Glitza IC, McQuade JL, Wang J, Zhang HC, Thompson JA, Thomas AS, Wang Y. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis. J Immunother Cancer 9(1), 2021. PMID: 33436487.
56. Panneerselvam K, Amin RN, Wei D, Tan D, Lum PJ, Zhang HC, Richards DM, Altan M, Grivas P, Thompson JA, Thomas AS, Wang Y. Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor-Related Esophagitis. J Natl Compr Canc Netw:1-9. e-Pub 2021. PMID: 34102607.
57. Ali H, Khurana S, Ma W, Peng Y, Jiang ZD, DuPont H, Zhang HC, Thomas AS, Okhuysen P, Wang Y. Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent Clostridioides difficile in cancer patients. J Cancer 12(21):6498-6506, 2021. e-Pub 2021. PMID: 34659541.
58. Zou F, Abu-Sbeih H, Ma W, Peng Y, Qiao W, Wang J, Shah AY, Glitza Oliva IC, Piha-Paul SA, Thompson JA, Zhang HC, Thomas AS, Wang Y. Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response. J Natl Compr Canc Netw:1-9. e-Pub 2020. PMID: 33316767.
59. Pinato DJ, Kaseb A, Wang Y, Saeed A, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Khan U, Lee C, Bulumulle A, Yu B, Paul S, Fessas P, Nimkar N, Bettinger D, Hildebrand H, Pressiani T, Abugabal YI, Personeni N, Huang YH, Lozano-Kuehne J, Rimassa L, Ang C, Marron TU. Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. J Immunother Cancer 8(2), 2020. PMID: 33028690.
60. Ibraheim H, Baillie S, Samaan MA, Abu-Sbeih H, Wang Y, Talley NJ, P Jones M, Powell N. Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis. Aliment Pharmacol Ther. e-Pub 2020. PMID: 32920854.
61. Fessas P, Kaseb A, Wang Y, Saeed A, Szafron D, Jun T, Dharmapuri S, Rafeh Naqash A, Muzaffar M, Navaid M, Khan U, Lee C, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Benevento F, Hildebrand H, Pressiani T, Abugabal YI, Personeni N, Huang YH, Rimassa L, Ang C, Marron T, Pinato DJ. Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. J Immunother Cancer 8(2), 2020. PMID: 32868393.
62. Pinato DJ, Kaneko T, Saeed A, Pressiani T, Kaseb A, Wang Y, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Lee CJ, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Ang C, Marron TU, Khan U, Personeni N, Rimassa L, Huang YH. Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers (Basel) 12(7), 2020. e-Pub 2020. PMID: 32664319.
63. Haanen J, Ernstoff M, Wang Y, Menzies A, Puzanov I, Grivas P, Larkin J, Peters S, Thompson J, Obeid M. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J Immunother Cancer 8(1), 2020. PMID: 32532839.
64. Thomas AS, Wang Y. Correspondence Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol. e-Pub 2020. PMID: 32530825.
65. Abu-Sbeih H, Faleck DM, Dougan M, Wang Y. Reply to Y. Inagaki et al. J Clin Oncol:JCO2000295. e-Pub 2020. PMID: 32250720.
66. Abu-Sbeih H, Ali FS, Chen E, Mallepally N, Luo W, Lu Y, Foo WC, Qiao W, Okhuysen PC, Adachi JA, Hachem RY, Altan M, Jenq RR, Wang Y. Neutropenic Enterocolitis: Clinical Features and Outcomes. Dis Colon Rectum 63(3):381-388, 2020. e-Pub 2019. PMID: 31842164.
67. Peng Y, Thomas AS, Wei D, Tan D, Wang Y. An Aggressive Approach Toward a Case of Refractory Ulcerative Colitis With Uncertain Etiology in the Context of Chronic Myeloid Leukemia. Inflamm Bowel Dis 26(4):e26-e27, 2020. PMID: 32016290.
68. Tang T, Abu-Sbeih H, Ma W, Lu Y, Luo W, Foo WC, Richards DM, Halperin DM, Ge PS, Wang Y. Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy. Clin Colorectal Cancer. e-Pub 2020. PMID: 32284253.
69. Chen E, Abu-Sbeih H, Thirumurthi S, Mallepally N, Khurana S, Wei D, Altan M, Morris VK, Tan D, Barcenas CH, Wang Y. Clinical characteristics of colitis induced by taxane-based chemotherapy. Ann Gastroenterol 33(1):59-67, 2020. e-Pub 2019. PMID: 31892799.
70. Abu-Sbeih H, Ali FS, Qiao W, Lum P, Shafi MA, Bresalier RS, Hawk E, Raju GS, Wang Y. Patients with non-colorectal cancers may be at elevated risk of colorectal neoplasia. J Cancer 11(11):3192-3198, 2020. e-Pub 2020. PMID: 32231724.
71. Abu-Sbeih H, Mallepally N, Goldstein R, Chen E, Tang T, Dike UK, Al-Asadi M, Westin S, Halperin D, Wang Y. Gastrointestinal toxic effects in patients with cancer receiving platinum-based therapy. J Cancer 11(11):3144-3150, 2020. e-Pub 2020. PMID: 32231718.
72. Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. J Clin Oncol:JCO1901674. e-Pub 2019. PMID: 31800340.
73. Abu-Sbeih H, Herrera LN, Tang T, Altan M, Chaftari AP, Okhuysen PC, Jenq RR, Wang Y. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. J Immunother Cancer 7(1):242, 2019. e-Pub 2019. PMID: 31488205.
74. Abu-Sbeih H, Ali FS, Tang T, Coronel E, Lee HJ, Pande M, Bresalier RS, Raju GS, Wang Y. Rate of colorectal neoplasia in patients with Hodgkin lymphoma. Colorectal Dis. e-Pub 2019. PMID: 31541529.
75. Abu-Sbeih H, Tang T, Ali FS, Luo W, Neelapu SS, Westin JR, Okhuysen PC, Foo WC, Curry JL, Richards DM, Ge PS, Wang Y. Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. Am J Clin Oncol. e-Pub 2019. PMID: 31478934.
76. Lee JH, Emelogu I, Kukreja K, Ali FS, Nogueras-Gonzalez G, Lum P, Coronel E, Ross W, Raju GS, Lynch P, Thirumurthi S, Stroehlein J, Wang Y, You YN, Weston B. Safety and efficacy of metal stents for malignant colonic obstruction in patients treated with bevacizumab. Gastrointest Endosc 90(1):116-124, 2019. e-Pub 2019. PMID: 30797835.
77. Abu-Sbeih H, Ali FS, Ge PS, Barcenas CH, Lum P, Qiao W, Bresalier RS, Bhutani MS, Raju GS, Wang Y. Patients with breast cancer may be at higher risk of colorectal neoplasia. Ann Gastroenterol 32(4):400-406, 2019. e-Pub 2019. PMID: 31263363.
78. Mallepally N, Abu-Sbeih H, Ahmed O, Chen E, Shafi MA, Neelapu SS, Wang Y. Clinical Features of Rituximab-associated Gastrointestinal Toxicities. Am J Clin Oncol 42(6):539-545, 2019. PMID: 31136371.
79. Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, Kendra K, Ricciuti B, Chiari R, De Giglio A, Sleiman J, Funchain P, Wills B, Zhang J, Naidoo J, Philpott J, Gao J, Subudhi SK, Wang Y. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. J Clin Oncol:JCO1900320. e-Pub 2019. PMID: 31163011.
80. Abu-Sbeih H, Chen E, Ahmed O, Mallepally N, Lum P, Qiao W, Lee HJ, Bresalier R, Wang LS, Weston B, Raju GS, Wang Y. Patients with Non-Hodgkin's Lymphoma Are at Risk of Adenomatous Colon Polyps. Dig Dis Sci. e-Pub 2019. PMID: 31053975.
81. Abu-Sbeih H, Tran CN, Ge PS, Bhutani MS, Alasadi M, Naing A, Jazaeri AA, Wang Y. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. J Immunother Cancer 7(1):118, 2019. e-Pub 2019. PMID: 31053161.
82. Tang T, Abu-Sbeih H, Luo W, Lum P, Qiao W, Bresalier RS, Richards DM, Wang Y. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scand J Gastroenterol 13:1-8. e-Pub 2019. PMID: 31079556.
83. Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, Bresalier RS, Charabaty A, Dadu R, Jazaeri A, Lashner B, Wang Y. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer 7(1):93, 2019. e-Pub 2019. PMID: 30940209.
84. Cynthia N. Tran, Hamzah Abu-Sbeih, Yang Lu, Wenyi Luo, Yinghong Wang. Vedolizumab achieved clinical and histological remission in a patient with lung cancer who had a steroid-refractory upper gastrointestinal injury due to nivolumab treatment. Journal of Immunotherapy and Precision Oncology 2(2):40-45, 2019.
85. Zhang HC, Luo W, Wang Y. Acute Liver Injury in the Context of Immune Checkpoint Inhibitor-related Colitis Treated with Infliximab. J Immunother Cancer 7(1):47, 2019. e-Pub 2019. PMID: 30777137.
86. Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, Dadu R, Coronel E, Wang Y. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer 7(1):31, 2019. e-Pub 2019. PMID: 30728076.
87. Abu-Sbeih H, Ali FS, Wang Y. Clinical Review on the Utility of Fecal Microbiota Transplantation in Immunocompromised Patients. Curr Gastroenterol Rep 21(4):8, 2019. e-Pub 2019. PMID: 30815766.
88. Abu-Sbeih H, Ali FS, Qiao W, Lu Y, Patel S, Diab A, Wang Y. Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunol Immunother. e-Pub 2019. PMID: 30666357.
89. Abu-Sbeih H, Ali FS, Coronel E, Chen HC, Wang X, Lum P, Shuttlesworth G, Bhutani MS, Raju GS, Lee JH, Stroehlein JR, Ross WA, Wang Y. Safety of Endoscopy in cancer patients with Thrombocytopenia and Neutropenia. Gastrointest Endosc. e-Pub 2018. PMID: 30550744.
90. Abu-Sbeih H, Ali FS, Alsaadi D, Jennings J, Luo W, Gong Z, Richards DM, Charabaty A, Wang Y. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer 6(1):142, 2018. e-Pub 2018. PMID: 30518410.
91. Cummings D, Cruise M, Lopez R, Roggenbuck D, Jairath V, Wang Y, Shen B, Rieder F. Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohn's disease of the pouch. Aliment Pharmacol Ther 48(11-12):1251-1259, 2018. e-Pub 2018. PMID: 30411391.
92. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. e-Pub 2018. PMID: 30420754.
93. Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 6(1):103, 2018. e-Pub 2018. PMID: 30305177.
94. Abu-Sbeih H, Choi K, Tran CN, Wang X, Lum P, Shuttlesworth G, Stroehlein JR, Okhuysen PC, Wang Y. Recurrent Clostridium difficile infection is associated with treatment failure and prolonged illness in cancer patients. Eur J Gastroenterol Hepatol. e-Pub 2018. PMID: 30339561.
95. Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer 6(1):95, 2018. e-Pub 2018. PMID: 30253811.
96. Choi K, Abu-Sbeih H, Samdani R, Nogueras Gonzalez G, Raju GS, Richards DM, Gao J, Subudhi S, Stroehlein J, Wang Y. Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?. Inflamm Bowel Dis. e-Pub 2018. PMID: 30169584.
97. Wang Y, Abu-Sbeih H, Mao E, Ali N, Qiao W, Trinh VA, Zobniw C, Johnson DH, Samdani R, Lum P, Shuttlesworth G, Blechacz B, Bresalier R, Miller E, Thirumurthi S, Richards D, Raju G, Stroehlein J, Diab A. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. Inflamm Bowel Dis 24(8):1695-1705, 2018. PMID: 29718308.
98. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA, National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714-1768, 2018. e-Pub 2018. PMID: 29442540.
99. Wang Y, Abu-Sbeih H, Mao E, Ali N, Ali FS, Qiao W, Lum P, Raju G, Shuttlesworth G, Stroehlein J, Diab A. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer 6(1):37, 2018. e-Pub 2018. PMID: 29747688.
100. Wang Y, Aggarwal P, Liu X, Lu H, Lian L, Wu X, Guo S, Aggarwal N, Lashner B, Shen B. Antiviral Treatment for Colonic Cytomegalovirus Infection in Ulcerative Colitis Patients Significantly Improved Their Surgery Free Survival. J Clin Gastroenterol 52(4):e27-e31, 2018. PMID: 27875354.
101. Abu-Sbeih h, Tang T, Ali F, Qiao W, Diab A, Wang Y. The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients’ outcomes. J Immunother Precis Oncol 1(1):7-18, 2018.
102. Tian Y, Abu-Sbeih H, Wang Y. Immune Checkpoint Inhibitors-Induced Hepatitis. Adv Exp Med Biol 995:159-164, 2018. PMID: 30539511.
103. Tian Y, Abu-Sbeih H, Wang Y. Immune Checkpoint Inhibitors-Induced Colitis. Adv Exp Med Biol 995:151-157, 2018. PMID: 30539510.
104. Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS, Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5(1):95, 2017. e-Pub 2017. PMID: 29162153.
105. Mehta PP, Kochhar G, Albeldawi M, Kirsh B, Rizk M, Putka B, John B, Wang Y, Breslaw N, Lopez R, Vargo JJ. Capnographic Monitoring in Routine EGD and Colonoscopy With Moderate Sedation: A Prospective, Randomized, Controlled Trial. Am J Gastroenterol 111(3):395-404, 2016. e-Pub 2016. PMID: 26902229.
106. Lai KK, Horvath B, Xie H, Wu X, Lewis BL, Pai RK, Plesec T, Patil DT, Gordon IO, Wang Y, Shen B, Goldblum JR, Liu X. Risk for colorectal neoplasia in patients with inflammatory bowel disease and mucosa indefinite for dysplasia. Inflamm Bowel Dis 21(2):378-84, 2015. PMID: 25569733.
107. Xu D, He CQ, He J, Yang H, Ma HM. Mitochondrial DNA sequence of the hybrid of Duroc (?) × [Landrace (?) × Yorshire (?)] pig. Mitochondrial DNA 26(5):682-3, 2015. e-Pub 2013. PMID: 24102607.
108. Xie H, Xiao SY, Pai R, Jiang W, Shadrach B, Carver P, Wang Y, Shen B, Zhou W, Liu X. Diagnostic utility of TP53 and cytokeratin 7 immunohistochemistry in idiopathic inflammatory bowel disease-associated neoplasia. Mod Pathol 27(2):303-13, 2014. e-Pub 2013. PMID: 23887291.
109. Wang Y, Atreja A, Wu X, Lashner BA, Brzezinski A, Shen B. Similar outcomes of IBD inpatients with Clostridium difficile infection detected by ELISA or PCR assay. Dig Dis Sci 58(8):2308-13, 2013. e-Pub 2013. PMID: 23525735.
110. Wang Y, Gong H, Lopez R, Lian L, Kiran RP, Soffer EE, Shen B. Correlation between serum serotonin and endoscopy inflammation scores in patients with ileal pouches. J Crohns Colitis 7(4):e133-42, 2013. e-Pub 2012. PMID: 22922006.
111. Wang Y, Lee H, Shen B. Systemic secondary amyloidosis in a 70-year-old patient with Crohn's disease: treatment with oral budesonide. Inflamm Bowel Dis 19(5):E74-5, 2013. PMID: 23478807.
112. Wang Y, Bennett AE, Cai H, Lian L, Shen B. Evaluation of upper and lower gastrointestinal histology in patients with ileal pouches. J Gastrointest Surg 16(3):572-80, 2012. e-Pub 2011. PMID: 22052108.
113. Wang Y, Shen B. Clostridium difficile-associated diarrhea in Crohn's disease patients with ostomy. Inflamm Bowel Dis 16(1):1-2, 2010. PMID: 19408324.
114. Cai H, Cebotaru V, Wang YH, Zhang XM, Cebotaru L, Guggino SE, Guggino WB. WNK4 kinase regulates surface expression of the human sodium chloride cotransporter in mammalian cells. Kidney Int 69(12):2162-70, 2006. e-Pub 2006. PMID: 16688122.
115. Wang Y, Cai H, Cebotaru L, Hryciw DH, Weinman EJ, Donowitz M, Guggino SE, Guggino WB. ClC-5: role in endocytosis in the proximal tubule. Am J Physiol Renal Physiol 289(4):F850-62, 2005. e-Pub 2005. PMID: 15942052.
116. Hara-Chikuma M, Wang Y, Guggino SE, Guggino WB, Verkman AS. Impaired acidification in early endosomes of ClC-5 deficient proximal tubule. Biochem Biophys Res Commun 329(3):941-6, 2005. PMID: 15752747.
117. Hryciw DH, Wang Y, Devuyst O, Pollock CA, Poronnik P, Guggino WB. Cofilin interacts with ClC-5 and regulates albumin uptake in proximal tubule cell lines. J Biol Chem 278(41):40169-76, 2003. e-Pub 2003. PMID: 12904289.
118. Fewell JE, Smith FG, Ng VK, Wong VH, Wang Y. Postnatal age influences the ability of rats to autoresuscitate from hypoxic-induced apnea. Am J Physiol Regul Integr Comp Physiol 279(1):R39-46, 2000. PMID: 10896862.
119. Msaouel P, Oromendia C, Siefker-radtke A, et. al.. Technology-enabled monitoring of patient-reported outcomes to detect and treat toxicities linked to immune checkpoint inhibitors.

Invited Articles

1. Gong Z, Wang Y. Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review. JCO Oncol Pract 16(8):OP2000002, 2020. e-Pub 2020. PMID: 32584703.
2. Abu-Sbeih H, Wang Y. Management Considerations for Immune Checkpoint Inhibitor-Induced Enterocolitis Based on Management of Inflammatory Bowel Disease. Inflamm Bowel Dis 26(5):662-668, 2020. e-Pub 2019. PMID: 31560045.
3. Abu-Sbeih H, Wang Y. Gut Microbiome and Immune Checkpoint Inhibitor-Induced Enterocolitis. Dig Dis Sci 65(3):797-799, 2020. e-Pub 2020. PMID: 32040664.
4. Abu-Sbeih H, Ali FS, Wang Y. Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management. Curr Opin Gastroenterol 36(1):25-32, 2020. PMID: 31609734.

Other Articles

1. Issac A, Szafron D, Wei D, Tan D, McQuade, J, Wang Y Encorafenib and binimetinib associated colitis: a case series. Case Rep Gastroenterol 16:388-393, 2022.
2. Amin R, Thomas AS, Khurana S, Panneerselvam K, Zou F, Ma W, Chari ST, Wang Y Management of Immune-Related Colitis During the COVID-19 Pandemic. Inflamm Bowel Dis 26(10):e110-e111, 2020. PMID: 32812047.
3. Wany Y, MacDermott R Topic Review-Clostridium Difficile Colitis. Albany Medical Review VIX(3), 2007.
4. Wang Y Case Report: A 78-year-old with Anorexia, Weakness, Shortness of Breath and Increased Abdominal Girth. Albany Medical Review VIII(3), 2006.

Abstracts

1. Amin R, Thomas AS, Wang Y. Fecal Transplant Sustained Colitis Remission on Immunotherapy Resumption. Annals of Internal Medicine Clinical Cases https://www.acpjournals.org/doi/10.7326/aimcc.2022.0490, 2022.
2. Sperling G, Wang Y. Diffuse metastatic melanoma in the GI lumen following immune checkpoint inhibitor colitis treatment. Case Rep Gastroenterol 2022 16(618-622), 2022.
3. Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, Dadu R, Coronel E, Wang Y. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer 7(1):31, 2019. e-Pub 2019. PMID: 30728076.
4. Ali FS, Abu-Sbeih H, Hicklen R, Wang Y. Fearing the Unknown – The Fate of Inflammatory Bowel Disease after Fecal Microbiota Transplantation in Clostridium difficile Infection. American College of Gastroenterology Annual Conference, 2018.
5. Abu-Sbeih H, Ali FS, Hicklen R, Wang Y. Fecal Microbiota Transplantation for Clostridium difficile Infection in Immunocompromised Patients – Safe or Risky?. American College of Gastroenterology Annual Conference, 2018.
6. Abi-Sbeih H, Ali FS, Hicklen R, Wang Y. Taming the Beast – The Safety and Efficacy of Fecal Microbiota Transplantation in Severe and Complicated Clostridium Difficile Infectino. American College of Gastroenterology Annual Conference, 2018.
7. Choi K, Abu-Sbeih H, Samdani R, Gonzalez GN, Raju GS, Richards D, Gao J, Subudhi S, Stroehlein J, Wang Y. Features of Microscopic Colitis in Cancer Patients Receiving Immune Checkpoint Inhibitors. American College of Gastroenterology Annual Conference, 2018.
8. Abu-Sbeih H, Ali F, Alsaadi D, Jennings J, Luo W, Gong Z, Richards D, Charabaty A, Wang Y. Outcomes of vedolizumab treatment in patients with immune checkpoint inhibitor induced diarrhea and colitis: A Multi-Center Study. American College of Gastroenterology Annual Conference oral presentation, 2018.
9. Tang T, Abu-Sbeih H, Luo W, Samdani R, Lum P, Qiao W, Bresalier, Richards D, Wang Y. The Constellation of Upper Gastrointestinal Symptoms and associated Endoscopic and Histologic Features in Patients Receiving Immune Checkpoint Inhibitors. American College of Gastroenterology Annual Conference, 2018.
10. Abu-Sbeih H, Ali FS, Qiao W, Lu Y, Patel S, Diab A, Wang Y. The Importance of Endoscopic and Histological Evaluation in the Management of Immune Checkpoint Inhibitor Induced Colitis. American College of Gastroenterology Annual Conference, 2018.
11. Abu-Sbeih H, Ali FS, Qiao W, Raju GS, Wang Y. Immune Checkpoint Inhibitor–Induced Colitis as a Predictor of Survival in Metastatic Melanoma. Society for Immunotherapy of Cancer, 2018.
12. Abu-Sbeih H, Tang T, Wang Y. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. Society for Immunotherapy of Cancer, 2018.
13. Abu-Sbeih H, Ali FS, Gao J, Wang Y. The fate of immune–mediated diarrhea after the resumption of immune checkpoint inhibitor treatment. Society for Immunotherapy of Cancer, 2018.
14. Wang Y, Abu-Sbeih H, Choi K, Wiesnoski D, Helmink B, Gopalakrishnan V, DuPont H, Jiang ZD, Tetzlaff M, Wargo J, Jeng RR. Fecal Microbiota Transplantation for refractory immune checkpoint inhibitor-associated colitis. Society for Immunotherapy of Cancer, 2018.
15. Abu-Sbeih H, Tang T, Richards DM, Westin JR, Neelapu SS Wang Y. Gastrointestinal symptoms observed after chimeric antigen receptor T–cell therapy. Society for Immunotherapy of Cancer, 2018.
16. Zhang CH, Luo W, Wang Y. Acute Liver Injury in the Context of Immune Checkpoint Inhibitor-related Colitis Treated with Infliximab. Society for Immunotherapy of Cancer, 2018.
17. Tran C, Abu-Sbeih H, Luo W, Wang y. Vedolizumab achieved clinical and histological remission in a patient with lung cancer who had a steroid-refractory upper gastrointestinal injury due to nivolumab treatment. Society for Immunotherapy of Cancer, 2018.
18. Abu-Sbieh H, Tang T, Qiao W, Johnson D, Diab A, Wang Y. Outcomes of immune-checkpoint inhibitor induced organ toxicities. American Society of Clinical Oncology annual meeting (abstract number 10063) 2018, JCO 36, 2018 (suppl; abstr 10063), 2018.
19. Abu-Sbeih H, Coronel E, Raju GS, Ross WA, Stroehlein JR, Lee JH, Bhutani M, Wang Y. Endoscopy Is Safe in Cancer Patients with Mild to Moderate Thrombocytopenia. DDW oral presentation 2018, GIE 87(6):AB92-AB93, 2018.
20. Abu-Sbeih H, Ali FS, Bhuani MS, Raj GS, Lee Jh, Stroehlein JR, Ross WA, Wang Y. Endoscopy is safe in cancer patients with mild to moderate neutropenia. GIE 87(6):AB128, 2018.
21. Abu-Sbieh H, Bhutani MS, Raju GS, Lee JH, Stroehlein JR, Ross WA, Wang Y. Predictors of overall survival in cancer patients who had endoscopic evaluation in the setting of neutropenia and thrombocytopenia. GIE 87(6):AB398-AB399, 2018.
22. Abu-Sbeih H, Irshad QUA, Stroehlein JR, Okhuysen PC, Wand Y. Multiple Recurrent Clostridium Difficile Infection Is Associated with Treatment Failure and Prolonged Illness in Cancer Patients. GIE 87(6):AB398-AB399, 2018.
23. Wang Y, Abu-Sbeih H, Mao E, Ali N, Ali FS, Faju GS, Stroehlein J, Diab A. Immune checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson Cancer Center. GIE 87(6):AB541-AB542, 2018.
24. Choi K, Samdani R, Wang Y. Systemic steroids in anti-PD1 induced collagenous colitis. Crohn’s and Colitis Congress meeting, 2018.
25. Choi K, Samdani R, Shuttlesworth G, Wang Y. Case series: immunotherapy-induced lymphocytic colitis. Crohn’s and Colitis Congress meeting, 2018.
26. Abu-Sbeih H, Shuttlesworth G, Samdani R, Zuazua R, Wang Y. Case series: immune-checkpoint inhibitors induced colitis treated with mesalamine. Crohn’s and Colitis Congress meeting, IBD 24 (suppl_1):S19-S19, 2018.
27. Abu-Sbeih H, Shuttlesworth G, Samdani R, Zuazua R, Wang Y. Immuno-checkpoint inhibitor induced colitis in a patient with lung cancer and colon metastasis treated with mesalamine: a case study. Crohn’s and Colitis Congress meeting 2018, IBD 24(suppl_1):S19-S19, 2018.
28. Ali F, Samdani R, Wang Y. Short term endoscopic follow up on immune-checkpoint inhibitor induced colitis post treatment. Crohn’s and Colitis Congress meeting, 2018.
29. Wang Y, DuPont H, Jian ZD, Jeng R, Zuazua R. Fecal microbiota transplant for immune-checkpoint inhibitor induced colitis in a 50 year old female with bladder cancer. Crohn’s and Colitis Congress meeting, 2018.
30. Wang Y, Abu-Sbeih H, Mao E, Ali N, Raju GS, Stroehlein J, Diab A. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. DDW poster 2018, GIE 87(6):AB541-AB542, 2018.
31. Ali N, Wang Y, Zuazua R. Patients with immunotherapy induced colitis can benefit from non-immunosuppressive agents. American College of Gastroenterology annual meeting, 2017.
32. Wang Y, Samdani R, Campbell M, Abraham S, Cotton I, Zuazua R. A Unique Case of Immunotherapy-Induced Colitis in a 50 Year Old Female with Bladder Cancer. American College of Gastroenterology annual meeting, 2017.
33. Wang Y, Samdani R, Bhutani M, Zuazua R, Kebriaei P. A Unique Case of GI GVHD in a 37 year old Male with AML. American College of Gastroenterology annual meeting, 2017.
34. Wang Y, Aggarwal P, Liu X, Lu H, Lian L, Wu X, Guo S, Aggarwal N, Lashner B, Shen B. Antiviral Treatment for Colonic Cytomegalovirus Infection in Ulcerative Colitis Patients Significantly Improved Their Surgery Free Survival. Ohio Gastroenterology Society, Columbus, OH, 2016.
35. Wang Y, Shen B. Fecal Microbiota Transplantation in Refractory Clostridium Difficile Pouchitis. Crohn's and Colitis Foundation Association, Orlando, FL, 2015.
36. Cummings D, Lopez R, Roggenbuck D, Wang Y, Shen B, Rieder F. Serum Anti-GP2 Antibody Isoforms 1 and 4 are Associated with Crohn's Disease of the Pouch in Patients with Ileal-Pouch Anal Anastomosis (IPAA). ACG, Honolulu, HI, 2015.
37. Mehta PP, Kochhar G, Albeldawi M, Kirsh B, Rizk M, Putka B, John B, Wang Y, Breslaw N, Lopez R, Vargo JJ. Capnographic Monitoring Does Not Improve Detection of Hypoxemia in Colonoscopy with Moderate Sedation. A Randomized, Controlled Trial. ACG, Philadelphia, PA, 2014.
38. Wang Y, Liu X, Lu H, Guo S, Lashner B, Shen B. Treatment for CMV Infection in UC Patients Significantly Decreased the Colectomy Rate. Crohn's and Colitis Foundation Association, Orlando, FL, 2014.
39. Asava-aree C, Mu E, Patel V, Feng J, Lian L, Achkar JP, Lashner B, Shen B, Wang Y. CMV Treatment Does Not Improve Clinical Outcomes in IBD Inpatients with CMV Colitis. ACG, San Diego, CA, 2013.
40. Wang Y, Bennett AE, Lopez R, Shen B. Endoscopy Alone Is Sufficient for Pouch Disease Activity Monitoring and Prediction of Pouch Outcomes. ACG, San Diego, CA, 2013.
41. Wang F, Wang Y. Sclerosing Mesenteritis in a 50-Year-Old Male Successfully Treated with Tamoxifen. ACP, Northern Illinois Regional, Chicago, IL, 2013.
42. Lai KK, Wang Y, Zie H, Shen B, Goldblum JR, Lewis BL, Liu X. Clinical Outcome after the Diagnosis of Indefinite for Dysplasia in Patients with Idiopathic Inflammatory Bowel Disease (IBD). United States & Canadian Academy of Pathology, Baltimore, MD, 2013.
43. Xie H, X SY, Pai R, Lai K, Wang Y, Shen B, Liu X. Diagnostic Utility of p53 and Cytokeratin 7 Immunohistochemistry in Idiopathic Inflammatory Bowel Disease-Associated Neoplasia. United States & Canadian Academy of Pathology, Baltimore, MD, 2013.
44. Mu E, Wu X, Atreja A, Feng J, Shen B, Lashner B, Wang Y. Analysis of Prevalence and Risk Factors for Active Disease of Crohn's Patients for Acute Exacerbation Symptoms. ACG, Las Vegas, NV, 2012.
45. Wang F, Jiang W, Pai R, Downs-Kelly E, Wang Y. Helicobacter Heilmannii Infection in A 43-Year-Old Female Effectively Treated with the Standard Triple Therapy. ACP, Chicago, IL, 2012.
46. Wang Y, Lee H, Shen B. Secondary Amyloidosis in a 70-Year-Old Patient with Crohn's Disease: Treatment with Oral Budesonide. ACG, Las Vegas, NV, 2012.
47. Wang Y, Atreja A, Wu X, Lashner BA, Brzezinski A, Shen B. Inflammatory Bowel Disease Patients with Clostridium Difficile Infection by ELISA or PCR Assay. Digestive Disease Week, San Diego, CA, 2012.
48. Wang Y, Atreja Ashish, Wu Xianrui, Lashner BA, Brzezinski A, Shen B. Risk Factors and Outcome of Hospitalized Inflammatory Bowel Disease Patients with Clostridium Difficile Infection by ELISA or PCR Assay. Digestive Disease Week, 2012.
49. Zhang C, Drazba J, Hatala D, Wang Y, Shen B. A Pilot Study: Development of A Novel Immunostaining Marker for Autoimmune Pouchitis. ACG, Washington, DC, 2011.
50. Wang Y, Gong H, Lopez R, Soffer E, Shen B. Correlation between Serum Serotonin and Symptom and Endoscopy Inflammation Scores in Patients with Ileal Pouches. Digestive Disease Week, Chicago, IL, 2011.
51. Wang Y, Bennett AE, Cai H, Shen B. Clinical Utility of Duodenal Histology in Diagnosis and Differential Diagnosis of Pouch Disorders. ACG, San Diego, CA, 2009.
52. Wang Y, Cai H, Shen B. Clinical Utility of Mucosal Healing in Patients with Pouchitis. ACG, San Diego, CA, 2009.
53. Wang Y, Ashley C. Leukemic Ascites: A Rare Cause of Acute Ascites. Am. J. Gastro, 2006.

Book Chapters

1. Abu-Sbeih H, Wang Y. Hepatobiliary Adverse Events. In: Adv Exp Med Biol, 271-276, 2020.
2. Abu-Sbeih H, Wang Y. Gastrointestinal Tract Adverse Events. In: Adv Exp Med Biol, 247-253, 2020.
3. Tian Y, Abu-Sbeih H, Wang Y. Management for checkpoint inhibitor induced colitis and hepatitis. In: Immunotherapy. 2nd. Springer: USA, 151-164, 2019.
4. 3. Faisal S Ali, Hamzah Abu-Sbeih, Emmaneul Coronel, Yinghong Wang. Hepatobiliary disease in the cancer patient leading to critical illness. In: Oncologic Critical Care. Springer: Switzerland, 2019.
5. Wang Y, Guggino WB, Fong P. Anion Channels. In: Seldin and Giebishch's The Kidney: Physiology and Pathophysiology. 4th. Elsevier, 769-787, 2007.

Books (edited and written)

1. Wang Y. Managing immunotherapy related organ toxicity, a practice guide. Ed(s) Y Wang. 1st Edition. Springer International Publishing, 2022.